Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other Accumulated Expenses (2017 - 2022)

Denali Therapeutics (DNLI) has disclosed Other Accumulated Expenses for 4 consecutive years, with $66.7 million as the latest value for Q4 2022.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $66.7 million in Q4 2022 year-over-year; TTM through Dec 2022 was $66.7 million, a N/A change, with the full-year FY2022 number at $66.7 million, changed N/A from a year prior.
  • Other Accumulated Expenses was $66.7 million for Q4 2022 at Denali Therapeutics, up from $24.0 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $66.7 million in Q4 2022 to a low of $47000.0 in Q2 2018.
  • A 3-year average of $11.0 million and a median of $1.1 million in 2019 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: surged 1480.95% in 2018, then soared 4442.55% in 2019.
  • Denali Therapeutics' Other Accumulated Expenses stood at $996000.0 in 2018, then skyrocketed by 2311.14% to $24.0 million in 2019, then skyrocketed by 177.71% to $66.7 million in 2022.
  • Per Business Quant, the three most recent readings for DNLI's Other Accumulated Expenses are $66.7 million (Q4 2022), $24.0 million (Q4 2019), and $3.5 million (Q3 2019).